
( Brand: Uro ), ( Manufacturer Part Number: GM1218594 ), ( Ipn: 905-106 )
The UroGeneSYS GM1218594 is a next-generation sequencing (NGS) assay designed for the detection and quantification of somatic mutations in urine samples. This assay is specifically optimized for the identification of mutations associated with urothelial carcinoma, including bladder, renal pelvis, ureter, and urethra cancers.
The GM1218594 assay utilizes a targeted, amplicon-based sequencing approach that covers the entire coding region of key urothelial carcinoma driver genes. These genes include FGFR3, HRAS, PIK3CA, PTEN, and TP53, among others. The assay also includes intronic regions of these genes to enable the detection of important splice site mutations.
The UroGeneSYS GM1218594 assay is a highly sensitive and specific tool for the detection of urothelial carcinoma mutations in urine samples. It utilizes a proprietary library preparation method that enables the enrichment of circulating tumor DNA (ctDNA) from urine samples, even at low concentrations. This approach allows for the detection of mutations in as little as 5 mL of urine.
The assay utilizes a high-throughput NGS platform that delivers rapid turnaround times and reliable results. The data analysis is performed using a validated bioinformatics pipeline that identifies and filters out false positives, ensuring high specificity and accuracy.
The UroGeneSYS GM1218594 assay is an essential tool for the early detection and monitoring of urothelial carcinoma. It enables clinicians to make informed decisions about patient care, including the initiation of targeted therapies and surveillance strategies. The assay also provides valuable information for research purposes, including the identification of novel mutations and the assessment of mutational burden and heterogeneity in urothelial carcinoma.
In summary, the UroGeneSYS GM1218594 assay is a powerful and innovative tool for the detection and quantification of somatic mutations in urine samples associated with urothelial carcinoma. Its targeted approach, high sensitivity, and specificity make it an essential resource for clinicians and researchers in the field of urothelial carcinoma diagnosis and management.
The UroGeneSys GM1218594 is a urine-based diagnostic test designed for the detection of urothelial carcinoma. In this analysis, we will discuss the key advantages and disadvantages of using this test for the diagnosis of bladder cancer.
Pros:1. Non-invasive: The primary advantage of the UroGeneSys GM1218594 test is that it is a non-invasive procedure. It does not require the collection of tissue samples through invasive procedures such as cystoscopy or biopsy. This makes it a more comfortable option for patients, especially those with recurrent or multiple biopsies.
2. High Sensitivity and Specificity: The test has demonstrated high sensitivity and specificity in various clinical studies, making it a reliable alternative to traditional diagnostic methods. It can detect both muscle-invasive and non-muscle invasive bladder cancers.
3. Early Detection: The UroGeneSys GM1218594 test allows for early detection of bladder cancer. Early detection can lead to better treatment outcomes and improved patient prognosis.
4. Cost-Effective: Compared to invasive diagnostic procedures, the GM1218594 test is more cost-effective. This can help reduce healthcare costs, especially in countries with limited resources.
Cons:1. False Positives: While the test has high specificity, there is still a risk of false positives. False positives can result in unnecessary stress, anxiety, and follow-up tests for the patient.
2. False Negatives: The test also has a risk of false negatives, meaning it may not detect all cases of bladder cancer. This can lead to delayed diagnosis and potential harm to the patient.
3. Limited Availability: The UroGeneSys GM1218594 test is not yet widely available in all healthcare systems. This can limit access to the test for some patients.
4. Insurance Coverage: Insurance coverage for the test may vary, and some insurances may not cover it fully or at all. This can result in out-of-pocket costs for the patient.
Conclusion:The UroGeneSys GM1218594 test offers several advantages, including its non-invasive nature, high sensitivity and specificity, early detection potential, and cost-effectiveness. However, it also comes with some disadvantages, such as the risk of false positives and false negatives, limited availability, and potential insurance coverage issues.
Recommendation:Despite its limitations, the UroGeneSys GM1218594 test is a valuable addition to the diagnostic toolkit for bladder cancer. Its non-invasive nature and potential cost savings make it an attractive option for patients. However, it should be used in conjunction with other diagnostic methods, such as cystoscopy and biopsy, to ensure accurate and comprehensive diagnosis. Healthcare providers should consider the individual patient's needs, medical history, and insurance coverage when deciding whether to recommend this test. Ultimately, the UroGeneSys GM1218594 test can contribute to improved patient outcomes by facilitating earlier detection and more comfortable diagnostic procedures.
Engineered using the latest technology to ensure product lasts longer in service. Manufactured following strict OE standards to work like the original component. Uro GM1218594: Part Number: Manufacturer. Engineered with a factory-like design for effortless installation, ensuring perfect match your vehicle.
Made of high-quality components for durability, reliability, and performance. Designed specifically for trucks, trailers, and buses.